IGFBP1 and metabolic dysfunction-associated steatohepatitis: Interestingly, neutralization of IGFBP1 prevented against NASH in Wtap-HKO mice, as revealed by lower serum ALT activity (Fig. 4i), less cleavage of caspase 3 (Fig. 4j), lower liver TAG levels (Fig. 4k), fewer hepatic lipid droplets (Fig. 4l) and less TUNEL-positive cells (Fig. 4m, n).